Under the agreement, OriGen will send maternal blood samples to Premaitha's clinical laboratory in the UK, which will analyze them using the firm's Iona test.
The study, published online in Prenatal Diagnosis last month, analyzed 40 websites from noninvasive prenatal test providers in detail.
The initiative aims to educate patients and healthcare providers about the benefits and limitations of NIPT screening and how to interpret the results.
Recent cost analyses funded by Ariosa and Natera found that NIPT could replace conventional screening in the US and be cost-neutral if provided at certain prices.
The researchers identified a large set of potential markers, and then narrowed them down to those with the most practical diagnostic potential.
Chromsomal array testing had a higher diagnostic yield in the study than standard procedures, and could have value as a first step before referring patients to further tests.
The change makes Anthem one of the first major payors to say that NIPT is medically necessary for the non-high-risk pregnancy population.
The Center for Human Genetics and Laboratory Medicine's Prenatalis test is based on Illumina's Verifi technology.
Birmingham Women's NHS Foundation Trust said it is partnering with Illumina to develop an NIPT, which it hopes to start offering in September.
SeraCare is licensing UCSF's T21, T18, and T13 trophoblast cell line materials to develop NIPT reference materials.
Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing.
Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.
Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.